Skip to content Skip to footer
Subscribe Now
Novo Nordisk
News

Novo Nordisk Reports Headline Results from P-IIIb (STEP UP) Study of Semaglutide 7.2mg in Obese Adults without Diabetes

Shots:The P-IIIb (STEP UP) study assessed semaglutide (7.2mg) vs semaglutide (2.4mg) & PBO as an adjunct to lifestyle intervention in obese adults (n=1,407; BMI ≥30kg/m^2) without diabetes for 72wks. STEP program also includes STEP UP T2D study of semaglutide (7.2mg) in obese adults (n=512) with T2D for 72wks. Study met its 1EP, depicting…
January 20, 2025

Read more

ThoughtSpot_Igor Zagradanin4
THOUGHTSPOT

Managing Chronic Conditions: Medication, Supplements, and Personalized Care Plans

Statistics show that at least 129 million people in the United States have a chronic illness. To effectively deal with chronic illnesses, one needs a thorough approach that includes customized supplements and medication. The management of these prolonged conditions requires consistent attention to prevent complexities while ensuring better living standards for patients.Continue reading to learn about…
July 26, 2024

Read more

VIEWPOINTS_Steffen-Sebastian Bolz_2023
VIEWPOINTS

Steffen-Sebastian Bolz, CSO of Aphaia Pharma Shares Insights from the P-II Study for Chronic Weight Management in Individuals with Obesity

Shots: Steffen shared the details of the first patient enrolled in the P-II study of Aphaia Pharma’s lead product APH-012 to induce weight loss in individuals with obesity He briefed the PharmaShots team about the study design of the P-II trial and also elaborated on the results from the P-I studyThe interview shows how…
February 27, 2023

Read more